Decode shared biology
Investigate inflammatory, fibrotic, metabolic, and vascular pathways linking cardiometabolic diseases more completely.
Why proteomics matters
Why proteomics matters for CKM research
Cardiovascular-kidney-metabolic (CKM) diseases are increasingly recognized as interconnected manifestations of shared biology rather than a collection of independent disorders. Profiling thousands of proteins across organ systems enables you to investigate the molecular pathways and endotypes potentially linking obesity, diabetes, chronic kidney disease, cardiovascular disease, and beyond.
Translate biomarker discovery
Generate protein insights that can inform potential biomarker strategies from large-scale discovery through translational research and toward potential future clinical applications.
Uncover molecular endotypes
Identify molecular subgroups potentially associated with cardiometabolic disease progression, therapeutic response, and biological heterogeneity.
Research approach
How Olink proteomics moves CKM research beyond traditional biomarkers
Olink proteomics helps you move your research from isolated biomarker measurements to broader protein insights across cardiovascular, kidney, liver, and other metabolic systems. Evidence from large-scale proteomics initiatives, cardiorenal outcome studies, and translational cohort studies shows how Olink proteomics is helping researchers discover meaningful protein signatures that can guide future clinical research investigating new approaches into how these diseases are diagnosed and treated.
Traditional isolated biomarker approach
Olink proteomics approach
Organized by individual diseases or separate organ systems.
Characterizes shared biology across the CKM continuum
Relies on a limited set of established biomarkers or endpoints.
Measures thousands of proteins across organ systems and biological pathways
Heterogeneity may remain unresolved due to limited characterization of disease drivers
Identifies molecular endotypes and responder subgroups based on protein signatures driving disease
Harder to scale consistently across complex study designs or large cohorts
Scalable technology for large cohorts and populations
Fragmented discovery-to-translational workflows may require switching of technologies or platforms
Enables platform continuity from discovery to translational and clinical research
Resources
Documents
Access key case studies, publications, and white papers demonstrating how proteomics is advancing cardio–kidney–liver–metabolic research, biomarker discovery and translational medicine.
| Documents | Type | File |
|---|---|---|
| Insights from precious samples in metabolomic and cardiovascular disease research | Flyer | Download PDF |
| Unlocking the Power of Proteomics: From Discovery to Application | Ebook |
Featured reading
Selected reading for CKM research
Explore key publications and articles demonstrating how proteomics advances cardiovascular-kidney-metabolic research, from identifying protein signatures associated with disease risk to uncovering mechanistic insights across multiple studies.
Access options
Bringing PEA technology into your research
Whether you are looking for full-service sample analysis, support from a Certified Service Provider, or want to run the assays in your own lab, you can access Olink solutions in a way that fits your study designs and infrastructure needs.
